Back to News
Market Impact: 0.25
Cologuard Plus® de Abbott recibe la marca CE para la detección del cáncer colorrectal en Europa
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Cologuard Plus, a noninvasive stool-based DNA screening test for colorectal cancer and advanced precancerous lesions, showed 95% sensitivity for colorectal cancer in the pivotal BLUE-C study. The excerpt provides no further study results, approval status, or commercial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally